Retatrutide research landscape and what it means for dosing Retatrutide is currently in Phase 3 clinical trials under the Eli Lilly TRIUMPH program
Mipomersen The drug mipomersen (Kynamro) is an anti-sense oligonucleotide (ASO) that targets the apoB mRNA in the liver, thereby resulting in reduced synthesis of the apoB-100 protein
Its role in research is exploratory and focused on mechanistic understanding, rather than producing therapeutic outcomes
These systemic benefits underscore how addressing metabolic dysregulation can optimize outcomes in inflammatory conditions, mirroring therapeutic insights established in rheumatoid arthritis management
You might need to look at your diet again, increase your physical activity, or change the dose of tirzepatide
Unfortunately, misinformation about these medications has also taken the Internet by storm